Drug intelligence / Profile preview

OVX-002

Development stage: Unknown
Lead developer: Ocuvex Therapeutics
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

OVX-002 is a small molecule corticosteroid ophthalmic solution being developed by Ocuvex Therapeutics for the management of post-surgical inflammation and pain, particularly following cataract surgery. The formulation utilizes a proprietary TJM (tight junction modulating) micellar platform technology designed to enhance drug penetration and delivery to ocular tissues. Administered as twice-daily eye drops, OVX-002 aims to provide effective inflammation control through a clear solution formulation. It is currently in Phase 1/2 clinical development.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on OVX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVX-002.

Explore the full profile